|
Cyclosporine(CsA) has been one of the main immunosuppressants after kidney transplantation since its introduction in Korea. There was remarkable improvement of graft survival in kidney transplantation with CsA, compared with azathioprine. Cipol-N(Chong Kun Dang, Korea), microemulsion gelatin capsule formulation of CsA, is a new generic drug. Incidence and severity of acute rejection, actual survival rate of patient and graft, function of the graft, pharmacokinetics of the Cipol-N, and the primary efficacy variables were evaluated 6 months after transplantation. Mean age of the patients was 37.1±10.4 years old. Male and female ratio was 42:17. There were 38 related pairs, which included 5 HLA identical and 33 HLA haplo-identical matches, and 21 unrelated pairs. A total of 10 patients were withdrawn from the study before post transplant 6 months_ There were 27 episodes of acute rejection in 25 patients, which were diagnosed clinically and pathologically. Steroid pulse therapy and anti lymphocyte agent were used in 24 and 3 cause respectively. There were 4 patients, who showed partial rescue but no graft loss due to acute rejection. Patient, and graft survival was 98.3% at post transplant 6 months. Serum creatinine concentration showed 1.3~1.7 mg/dl at through the study period, which meant relatively stable graft function. With this short term study, we can report that Cipol-N showed relatively good efficacy in primary living donor kidney transplantation.
|